In vitro study demonstrates dual-halogen NanoSIMS imaging resolves individual double-stranded RNA strands in HepG2 cells, highlighting a method to optimize RNA therapeutic stability.
Oligonucleotide drugs, such as small interfering RNAs (siRNAs) and small activating RNAs (saRNAs), are rapidly advancing in the clinic. However, a complete picture of their intracellular uptake, trafficking, and fate remains elusive. Additionally, the double-stranded nature of the compounds makes it challenging to track both the guide and passenger strands individually. To address this, we present a proof-of-concept study of nanoscale secondary ion mass spectrometry (NanoSIMS) in combination with a dual-labeling strategy using 5-bromo- and 5-iodo-modified uracil to detect, discriminate, and quantify both strands without relying on bulky fluorescent tags. By evaluating GalNAc-conjugated siRNAs and saRNAs in HepG2 cells, we demonstrate that NanoSIMS can effectively codetect guide and passenger strands within the endolysosomal compartments. For the siRNA design, imaging revealed, as expected, a robust correlation between the strands. Conversely, we highlight the use of NanoSIMS as a potential aid in the optimization of guide strand stability by exploring different chemical designs for the saRNA. This work highlights the potential of NanoSIMS to quantitatively monitor individual double-stranded RNA strands and their subcellular localization in vitro, offering a valuable tool to generate critical trafficking and quantitative data for oligonucleotide therapeutics.
No takes yet. Share an insight, caveat, or question.
Vicentini et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: